Radiation necrosis remains one of the most difficult complications in neuro-oncology.
It can cause neurological symptoms, worsen quality of life, and closely mimic tumor recurrence on standard imaging. This creates a major clinical dilemma: whether a patient needs treatment for radiation injury, treatment for tumor progression, or both.
A new consensus statement from the European Association for Neuro-Oncology provides practical guidance for the diagnosis and management of radiation necrosis in patients with brain tumors.
Published in Neuro-Oncology, the statement was developed through a structured Delphi process involving an international multidisciplinary expert panel.
Why This Consensus Matters
Radiation necrosis can develop after radiotherapy for primary brain tumors or brain metastases.
The reported incidence varies widely, from 4% to 30%, largely because it is difficult to diagnose consistently. Fewer than 10% of cases are symptomatic, but when symptoms occur, they can be clinically significant.
Radiation necrosis usually appears 6 to 24 months after radiotherapy, although delayed cases can occur several years later.
The condition is particularly challenging because it can look similar to tumor recurrence on imaging. This can lead to inappropriate escalation of anti-tumor therapy, unnecessary re-irradiation, or delayed salvage treatment if true progression is missed.
How the Consensus Was Developed
The EANO expert panel used a 3-round Delphi process.
The group included experts from radiation oncology, neuro-oncology, medical oncology, neurosurgery, neuropathology, radiology, and nuclear medicine.
The panel reviewed available literature and formulated statements across several domains, including definition, pathophysiology, causes, imaging, pathology, management, and future research.
Consensus was defined as at least 80% agreement.
After three rounds, consensus was reached on 53 of 57 statements.
What Is Radiation Necrosis?
The consensus defines radiation necrosis as an entity based on a combination of clinical, radiological, and histopathological features.
None of these features is fully specific when considered alone.
Radiation necrosis may be asymptomatic or symptomatic. It may also coexist with tumor recurrence, creating mixed lesions that are even harder to interpret.
Pathophysiologically, radiation necrosis is considered a complex, multifactorial process involving injury to the tumor microenvironment, vascular damage, glial injury, inflammation, blood-brain barrier disruption, and perilesional edema.
Key Risk Factors
The panel emphasized that radiation necrosis risk is influenced mainly by radiotherapy-related factors.
Important risk factors include higher total dose, larger fraction size, larger irradiated volume, re-irradiation, and some combinations with systemic therapy.
For single-session stereotactic radiosurgery, the volume of normal brain receiving 12 Gy is an important predictor. If V12Gy is higher than 10 cm³, the risk of radiation necrosis increases, and hypofractionated treatment should be considered.
The panel also noted that fractionation reduces the risk of radiation necrosis.
Re-irradiation increases risk, and systemic therapies given before, during, or after radiotherapy may increase the risk in patients with brain metastases.
At present, there are no clear patient-related factors such as age, sex, or comorbidity that consistently predict radiation necrosis.
Diagnosis Remains Difficult
Radiation necrosis and tumor progression cannot be reliably distinguished by symptoms alone.
Both may present with new or worsening focal neurological deficits, seizures, cognitive decline, headache, nausea, or signs of increased intracranial pressure.
Both may also be asymptomatic.
The consensus therefore emphasizes an integrated diagnostic approach, combining clinical assessment, advanced imaging, and histopathology when needed.
Imaging Recommendations
Standard T1-weighted contrast-enhanced MRI alone has limited sensitivity and specificity for distinguishing radiation necrosis from tumor recurrence.
The EANO panel recommends adding advanced MRI sequences when a new contrast-enhancing lesion is suspicious for either recurrence or radiation necrosis.
The most useful advanced MRI tools in routine practice are MR perfusion and MR spectroscopy.
High perfusion and elevated choline are more suggestive of tumor recurrence.
Low or moderate perfusion and increased lactate are more suggestive of radiation necrosis.
The consensus also supports the use of amino acid PET imaging, including FET, F-DOPA, or MET PET, to help differentiate radiation necrosis from tumor relapse.
Advanced MRI combined with amino acid PET provides the highest diagnostic accuracy.
Role of Pathology
Histopathology remains the gold standard when the diagnosis is uncertain.
However, pathology is not always straightforward.
In irradiated gliomas, distinguishing viable tumor cells from reactive glial cells can be difficult because of overlapping cytological features.
In brain metastases, immunohistochemical lineage markers can improve detection and quantification of viable tumor cells within necrotic tissue.
For IDH-mutant and diffuse midline gliomas, mutation-specific antibodies such as IDH1 R132H and H3 K27M can help distinguish viable tumor cells from treatment-related changes.
The panel also noted that there is currently no standardized reporting format for documenting radiation necrosis in neuropathological specimens.
When to Treat
The consensus recommends symptom-driven management.
Radiological findings alone should not trigger pharmacological treatment.
Treatment should be considered when neurological symptoms are present, especially when symptoms last more than 7 days or increase in severity in the presence of imaging findings suggestive of radiation necrosis.
Symptoms may include headache, seizures, cognitive impairment, dysphasia, hemiparesis, ataxia, or other focal neurological deficits.
Asymptomatic patients can generally be observed with serial imaging.
Corticosteroids
Corticosteroids remain a commonly used first-line treatment, mainly because they are accessible, oral, and can rapidly reduce edema.
The panel emphasized that dexamethasone dosing should not follow a fixed high-dose approach.
Instead, clinicians should use the minimum effective dose that provides clinical and/or radiological benefit.
Steroid tapering should be guided mainly by clinical stability and patient-reported symptoms, not imaging alone.
Radiological improvement is important, but it does not always match symptom improvement.
If neurological symptoms worsen during steroid therapy and imaging also suggests worsening radiation necrosis, escalation of treatment should be considered. However, tumor progression should also remain in the differential diagnosis.
Bevacizumab
Bevacizumab is recommended as an important option for steroid-refractory or steroid-dependent symptomatic radiation necrosis.
The panel recommends considering bevacizumab when symptoms remain steroid-dependent for more than 4 weeks or when a daily dexamethasone dose of 8 mg or equivalent is still needed.
Bevacizumab works by targeting VEGF-A, helping normalize the abnormal blood vessel environment, reduce vascular leakiness, restore the blood-brain barrier, and decrease edema.
Several dosing regimens are used in practice, but there is no clearly established best dose, interval, or duration.
The consensus notes that bevacizumab is usually well tolerated at the doses used for radiation necrosis, but possible risks include hypertension, wound healing problems, venous thromboembolism, pulmonary embolism, and small risks of cerebral hemorrhage or infarction.
Surgery and LITT
Surgery should be considered whenever it is feasible and safe.
Surgical resection can provide both definitive diagnosis and rapid symptom relief, especially in accessible lesions, rapidly deteriorating patients, or cases where medical therapy is insufficient.
It can also help reduce corticosteroid dependency.
Laser interstitial thermal therapy may be considered for treatment-resistant radiation necrosis when continued steroids or repeated bevacizumab cycles are required and surgical resection is not suitable.
However, LITT is not available in all centers, and more evidence is needed to define its role.
Practical Treatment Flow
The consensus includes a clinical flowchart for suspected radiation necrosis.
The approach begins with detection of a new or enlarging contrast-enhancing lesion on MRI, followed by assessment of symptoms.
Advanced diagnostic workup includes MR perfusion and/or MR spectroscopy, with amino acid PET as a complementary tool.
High perfusion, high choline, or high PET uptake suggests tumor recurrence.
Low perfusion, increased lactate, or low PET uptake suggests radiation necrosis.
If doubt remains and the lesion is accessible, biopsy or surgery should be considered.
For asymptomatic radiation necrosis, observation with serial imaging is appropriate.
For symptomatic cases, dexamethasone is used first, bevacizumab is considered for steroid-refractory or steroid-dependent disease, and surgery is preferred when rapid deterioration or accessible lesions make resection appropriate.
Research Gaps
The consensus also highlights major evidence gaps.
There is still no level 1 evidence for many aspects of radiation necrosis diagnosis and treatment.
Key research priorities include predictive factors, biological mechanisms, diagnostic accuracy, prevention strategies, novel therapies, grading of severity, the role of bevacizumab biosimilars, cost-effectiveness of first-line bevacizumab, and better clinical trial designs.
The authors emphasize the need for prospective randomized trials, particularly in symptomatic radiation necrosis.
Clinical Takeaway
The EANO consensus statement provides practical guidance for a difficult and common neuro-oncology problem.
Radiation necrosis should be approached through multidisciplinary assessment, using clinical evaluation, advanced MRI, amino acid PET, and histopathology when needed.
Management should be driven by symptoms rather than imaging alone.
Corticosteroids may be used initially, bevacizumab is recommended for steroid-refractory or steroid-dependent cases, and surgery should be considered when feasible for diagnosis and symptom relief.
Although high-level evidence remains limited, this consensus offers a structured approach for clinicians managing radiation necrosis after brain radiotherapy.
Read full article here.